Sheng, X., Zhang, C., Du, P., Cao, Y., Zhou, L., Wang, Y., Yang, K., Ji, Y., Zou, B., Huang, H., Liu, Y., Bai, X., Feng, D., Yang, Y., Bian, J., Yu, Z., Niu, H., Fang, J., He, Z., Guo, J. (2026). Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.766